文献速递前列腺癌

基于原发肿瘤特征预测根治性前列腺切除术后生化复发

Prediction of biochemical recurrence after radical prostatectomy from primary tumour characteristics.
PubMed 文献 · BJU Int · 2024-09-11

研究在澳大利亚与荷兰两中心846例患者中构建并外部校准了纳入临床与现代影像特征的根治性前列腺切除术后早期生化复发预测模型,发现诊断性PSMA-PET/CT的原发肿瘤SUVmax与更差的3年生化复发无生存期相关。

要点

  • 肿瘤SUVmax升高与术前和术后模型预测的3年生化复发无生存期更差相关。
  • 典型术前参数患者SUVmax从4升至16,预测3年BRFS从66%降至42%。
  • 外部校准样本n=464表现合理,但对预后良好患者有高估生存倾向。

核心结论

  • 诊断性PSMA-PET/CT的原发肿瘤SUVmax在常用变量之外对预测根治性前列腺切除术后生化复发无生存期具有附加价值。

研究设计与样本

  • 在澳大利亚与荷兰两中心接受根治性前列腺切除术前完成多参数磁共振成像、前列腺活检和PSMA-PET/CT的患者中构建预测模型。
  • 使用846例澳大利亚样本开发比例风险模型预测事件时间,并在荷兰外部数据集(n=464)以相同纳入标准评估校准。

主要发现

  • 肿瘤SUVmax与术前和术后模型预测的更差3年生化复发无生存期均相关。
  • 65岁、PSA 8 ng/mL、PI-RADS评分4/5、活检Gleason评分≥4+5的典型术前参数患者,SUVmax从4升至16使预测3年BRFS从66%降至42%。
  • 同年龄和PSA水平但病理分期pT3a、根治性前列腺切除标本Gleason评分≥4+5、切缘阴性的患者,SUVmax从4升至16使预测3年BRFS从76%降至61%。
  • 外部样本(n=464)校准表现合理,但观察到对预后良好患者有高估生存的倾向。

关键数值与推荐

  • 生化复发定义为PSA水平升高≥0.2 ng/mL或临床医生酌情启动术后治疗。
  • 预测模型纳入术前和术后相关参数及诊断性PSMA-PET/CT原发肿瘤最大标准化摄取值(SUVmax)。

局限性

  • 外部校准样本中观察到对预后良好患者有高估生存的倾向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To construct and externally calibrate a predictive model for early biochemical recurrence (BCR) after radical prostatectomy (RP) incorporating clinical and modern imaging characteristics of the primary tumour. PATIENTS AND METHODS: Patients who underwent RP following multiparametric magnetic resonance imaging, prostate biopsy and prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT), from two centres in Australia and the Netherlands. The primary outcome was biochemical recurrence-free survival (BRFS), where BCR was defined as a rising PSA level of ≥0.2 ng/mL or initiation of postoperative treatment per clinician discretion. Proportional hazards models to predict time to event were developed in the Australian sample using relevant pre- and post-surgical parameters and primary tumour maximum standardised uptake value (SUVmax) on diagnostic PSMA-PET/CT. Calibration was assessed in an external dataset from the Netherlands with the same inclusion criteria. RESULTS: Data from 846 patients were used to develop the models. Tumour SUVmax was associated with worse predicted 3-year BRFS for both pre- and post-surgical models. SUVmax change from 4 to 16 lessened the predicted 3-year BRFS from 66% to 42% for a patient aged 65 years with typical pre-surgical parameters (PSA level 8 ng/mL, Prostate Imaging-Reporting and Data System score 4/5 and biopsy Gleason score ≥4 + 5). Considering post-surgical variables, a patient with the same age and PSA level but pathological stage pT3a, RP Gleason score ≥4 + 5 and negative margins, SUVmax change from 4 to 16 lessened the predicted 3-year BRFS from 76% to 61%. Calibration on an external sample (n = 464) showed reasonable performance; however, a tendency to overestimate survival in patients with good prognostic factors was observed. CONCLUSION: Tumour SUVmax on diagnostic PSMA-PET/CT has utility additional to commonly recognised variables for prediction of BRFS after RP.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Roberts MJ, Papa N, Veerman H, et al. Prediction of biochemical recurrence after radical prostatectomy from primary tumour characteristics. BJU Int. 2024. PMID: 39262180. doi:10.1111/bju.16482

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。